



Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

May 5, 2026

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at <http://ir.fractyl.com>. The webcast will be archived and available for replay following the live event.

The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 9:20 a.m. PT (12:20 p.m. ET).

A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at <http://ir.fractyl.com>. The webcast will be archived and available for replay following the live event.

About Fractyl Health

Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Contact

Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200